Hostname: page-component-848d4c4894-x24gv Total loading time: 0 Render date: 2024-06-08T13:00:12.555Z Has data issue: false hasContentIssue false
  • English
  • Français

Comparison of risperidone, olanzapine and quetiapine: effects on body weight, serum blood glucose and prolactin

Published online by Cambridge University Press:  02 January 2018

Haroon Rashid Chaudhry ,
Nadia Arshad ,
Saima Niaz ,
Tahir Suleman  and
Khalid A. Mufti
Haroon Rashid Chaudhry
Affiliation:
Department of Psychiatry, Fatima Jinnah Medical College, Lahore, Pakistan, email pprc@wol.net.pk
Nadia Arshad
Affiliation:
Research, College of Physicians and Surgeons Pakistan
Saima Niaz
Affiliation:
Trust Grade (Adult Psychiatry), Plymouth Teaching Primary Care Trust, Mount Gould Hospital, Plymouth, UK
Tahir Suleman
Affiliation:
(Working Age), Cumbria Partnership NHS Foundation Trust, Carlisle, UK
Khalid A. Mufti
Affiliation:
Horizon, Peshawar, Pakistan
Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Schizophrenia is a chronic illness with a lifetime prevalence of 1% and with serious physical, social and economic consequences. Over the past decade, atypical antipsychotic medications have become the first-line treatment for schizophrenia (Breier et al, 2005).

Type
Original papers
Information
International Psychiatry , Volume 5 , Issue 3 , July 2008 , pp. 71 - 73
Creative Commons
Creative Common License - CCCreative Common License - BYCreative Common License - NCCreative Common License - ND
This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits noncommercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.
Copyright
Copyright © Royal College of Psychiatrists 2008

References

Allison, D. B., Mentore, J. L., Heo, M., et al (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry, 156, 1686–1696.Google Scholar
American Diabetes Association (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27, 596–601.Google Scholar
Breier, A., Berg, P. H., Thakore, J. H., et al (2005) Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. American Journal of Psychiatry, 162, 1879.Google Scholar
Bryden, K. E. & Kopala, L. C. (1999) Body mass index increase of 58% associated with olanzapine. American Journal of Psychiatry, 156, 1835–1836.Google Scholar
Gupta, S., Masand, P. S. & Virk, S. (2004) Weight decline in patients switching from olanzapine to quetiapine. Schizophrenia Research, 70, 57–62.Google Scholar
Lindenmayer, J. P., Czobor, P., Volavka, J., et al (2003) Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. American Journal of Psychiatry, 160, 290–296.Google Scholar
Sachetti, E., Valsecchi, P. & Regeni, C. (2003) Comparison of quetiapine, olanzapine and risperidone in patients with schizophrenia: interim results of a randomised, rater-blinded study. European Neuropsychopharmacology, 13, S350.CrossRefGoogle Scholar
Straker, D., Correll, C. U. & Kramer-Ginsberg, E. (2005) Cost effective screening for the metabolic syndrome in patients treated with second generation antipsychotic medication. American Journal of Psychiatry, 162, 1217–1221.Google Scholar
Svesta, J., Synek, O. & Zourkova, A. (2003) A double-blind comparison of olanzapine and quetiapine in the treatment of acute exacerbations of schizophrenic disorders. European Neuropsychopharmacology, 13, S291.Google Scholar
Taylor, D. M. & McAskill, R. (2000) Atypical antipsychotics and weight gain – a systematic review. Acta Psychiatrica Scandinavica, 101, 416–432.Google Scholar
Tran, P. V., Hamilton, S. H. & Kuntz, A. J. (1997) Double blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Journal of Clinical Psychopharmacology, 17, 407–418.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.